ATOR-1017, a 4-1BB antibody developed for tumor-directed immunotherapy of cancer

被引：0
|
作者：
Werchau, Doreen [1 ]
Rosen, Anna [2 ]
Eriksson, Mia [1 ]
Jarnum, Sofia [1 ]
Furebring, Christina [1 ]
Smith, Karin Enell [1 ]
机构：
[1] Alligator Biosci AB, Lund, Sweden
[2] Alligator Biosci, Lund, Sweden
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P608
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Targeting 4-1BB Costimulation to the Tumor Stroma with Bispecific Aptamer Conjugates Enhances the Therapeutic Index of Tumor Immunotherapy
    Schrand, Brett
    Berezhnoy, Alexey
    Brenneman, Randall
    Williams, Anthony
    Levay, Agata
    Kong, Ling-Yuan
    Rao, Ganesh
    Zhou, Shouhao
    Heimberger, Amy B.
    Gilboa, Eli
    CANCER IMMUNOLOGY RESEARCH, 2014, 2 (09) : 867 - 877
  • [42] Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy
    Schrand, Brett
    Berezhnoy, Alexey
    Brenneman, Randall
    Williams, Anthony
    Levay, Agata
    Kong, Ling-Yuan
    Rao, Ganesh
    Zhou, Shouhao
    Heimberger, Amy
    Gilboa, Eli
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (10)
  • [43] Tumor-mediated 4-1BB induces tumor proliferation and metastasis in the colorectal cancer cells
    Kim, Min-Kyoung
    Shin, Kyung-Ju
    Bae, Sijeong
    Seo, Jin-Myung
    Jung, Hosun
    Moon, Young-ah
    Yang, Su-Geun
    LIFE SCIENCES, 2022, 307
  • [44] A novel form of 4-1BB ligand has better efficacy than agonistic 4-1BB antibody as well as TLR agonists in a peptide based cancer vaccine
    Sharma, Rajesh K.
    Elpek, Kutlu G.
    Yolcu, Esma S.
    Schabowsky, Rich-Henry
    Zhao, Hong
    Bandura-Morgan, Laura L.
    Shirwan, Haval
    JOURNAL OF IMMUNOLOGY, 2009, 182
  • [45] Development of a novel MSLN x 4-1BB bispecific antibody
    Li, Liangwei
    Zhang, Dayan
    Shen, Guodong
    Liu, Wenting
    Zeng, Xiaoli
    Wu, Lingling
    Zhao, Qun
    Zhou, Weiming
    Huang, Yang
    Cheng, Liansheng
    CANCER RESEARCH, 2023, 83 (07)
  • [46] Beneficial outcome of combination therapy with 4-1BB targeting antibody
    Ramelet, M.
    Mirjolet, J. F.
    France, D.
    Morgand, L.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S96 - S97
  • [47] Mechanisms underlying 4-1BB agonist antibody mediated hepatotoxicity
    Bartkowiak, Todd
    Jaiswal, Ashvin R.
    Ai, Midan
    Budhani, Pratha
    Ager, Casey
    Curran, Michael A.
    JOURNAL OF IMMUNOLOGY, 2016, 196
  • [48] Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy
    Liu, Guizhong
    Luo, Peter
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [49] The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
    Claus, Christina
    Ferrara-Koller, Claudia
    Klein, Christian
    MABS, 2023, 15 (01)
  • [50] The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy
    Moran, Amy E.
    Kovacsovics-Bankowski, Magdalena
    Weinberg, Andrew D.
    CURRENT OPINION IN IMMUNOLOGY, 2013, 25 (02) : 230 - 237
12345